Late Breaking Clinical Trials

Scientific Sessions 2017

Scientific Sessions: November 11–15

Resuscitation Science Symposium: November 11–13

Cardiovascular Nursing Clinical Symposium: November 13–14

Anaheim, California

Materials related to Late Breaking Clinical Trials will be released after time of presentation.

Sunday, Nov. 12

Late Breaking Clinical Trials 1: CABG and EP Peri-procedural Dilemmas
C David Mazer

TRiCS III - An International Multicenter Randomized Trial of Transfusion Requirements in Cardiac Surgery
C David Mazer | St. Michael's Hospital, University of Toronto, Toronto, ON, Canada


Qiang Zhao

DACAB: Efficacy and Safety of Dual Acetylsalicylic Acid plus Ticagrelor or Ticagrelor Alone Antiplatelet Strategy after Coronary Artery Bypass Surgery at 12 months: A Randomized Multicentre Trial
Qiang Zhao | Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China


Steven Weisbord

PRESERVE: Sodium Bicarbonate and N-Acetylcysteine for the Prevention of Serious Adverse Outcomes Following Angiography
Steven Weisbord | University of Pittsburgh, Pittsburgh, PA


David Birnie

BRUISE CONTROL-2: A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-Coagulant at the Time of Device Surgery
David H Birnie | University of Ottawa Heart Institute, Ottawa, ON, Canada


Akihiko Nogami

ABRIDGE J: Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial
Akihiko Nogami | University of Tsukuba, Tsukuba, Japan


Monday, Nov. 13

Late Breaking Clinical Trials 2: Late Breaking Science in Prevention
Marc Sabatine

REAL-CAD: Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease
Takeshi Kimura | Kyoto University Graduate School of Medicine, Kyoto, Japan


Louise Bowman

REVEAL: Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes
Louise Bowman | University of Oxford, Oxford, United Kingdom


Marc Bonaca

FOURIER: Evolocumab and Outcomes in Patients With Peripheral Artery Disease
Marc P Bonaca | Brigham & Women's Hospital, Boston, MA


Marc Sabatine

Clinical Benefit of Evolocumab in Patients With a History of MI: An Analysis From FOURIER
Marc S Sabatine | Brigham & Women's Hospital, Boston, MA



Late Breaking Clinical Trials 3: Latest Insights into Hypertension Management
Mar Pujades-Rodriguez

BP TITRE: Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality
Mar Pujades-Rodriguez | Leeds Institute of Biomedical and Clinical Sciences, Leeds, United Kingdom


Karen Johnson

SPRINT: Blood Pressure Measurement in the Systolic Blood Pressure Intervention Trial
Karen C Johnson | University of Tennessee Health Science Center, Memphis, TN


Carlos Schiavon

GATEWAY: Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial
Carlos A Schiavon | Heart Hospital - HCor, São Paulo, Brazil


Late Breaking Clinical Trials 4: Sweet Spot in Cardiometabolic Care
Kenneth Mahaffey

CANVAS: Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Kenneth W. Mahaffey | Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA


Robert Mentz

EXSCEL: Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights From the EXSCEL Trial
Robert J Mentz | Duke University School of Medicine, Durham, NC


Subodh Verma

EMPA-REG OUTCOME: Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients With Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
Subodh Verma | St Michael's Hospital, University of Toronto, Toronto, ON, Canada


Tanja Zeller

BiomarCaRE: Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population - The Biomarcare Consortium
Tanja Zeller | University Heart Center Hamburg, Hamburg, Germany


Tuesday, Nov. 14

Late Breaking Clinical Trials 5: New Insights into the Risks, Benefits, and Costs of Antithrombotic Therapy
Andre Lamy Headshot

COMPASS: Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial
Andre Lamy | Population Health Research Institute, Hamilton, ON, Canada


Jonas Oldgren Headshot

RE-DUAL PCI: Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Jonas Oldgren | Uppsala University, Uppsala, Sweden


Michelle M Graham Headshot

POISE-2 PCI: Aspirin in Patients With Previous Percutaneous Coronary Intervention (PCI) Undergoing Noncardiac Surgery: The POISE-2 PCI Substudy
Michelle M Graham | University of Alberta, Edmonton, AB, Canada


ss17_E_magnus_ohman_headshot

GEMINI-ACS-1: P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
E Magnus Ohman | Duke Clinical Research Institute, Durham, NC


Zuzana Motovska Headshot

PRAGUE-18: One-Year Outcomes of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty and Randomized to Prasugrel versus Ticagrelor. The Prague-18 Trial
Zuzana Motovska |Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic

Late Breaking Clinical Trials 6: Evaluating Quality Improvement and Patient Centered Care Interventions
Karolina Szummer Headshot

SWEDEHEART: Improved Outcomes in Patients With Non-ST-Elevation Myocardial Infarction During 20 Years are Related to Implementation of Evidence Based Treatments - Results From the SWEDEHEART Registry 1995-2014
Karolina Szummer | Karolinska University Hospital, Stockholm, Sweden


STIC2IT: Results of the Study of a Tele-Pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence
Niteesh Kumar Choudhry | Brigham and Women's Hospital, Boston, MA


ACS QUIK: Effect of a Quality Improvement Toolkit on Acute Myocardial Infarction in India: The ACS QUIK Cluster Randomized, Stepped Wedge Trial
Mark D Huffman | Northwestern University, Chicago, IL


Martin Than Headshot

ICARE-ACS: National Implementation of a Clinical Guidance Framework for the Emergency Department Assessment of Patients With Possible Acute Coronary Syndromes
Martin Than | Christchurch Hospital, Christchurch, New Zealand


Larry A Allen Headshot

DECIDE-LVAD: Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure: The DECIDE-LVAD Trial
Larry A Allen | University of Colorado Denver, Aurora, CO


STEMI ACCELERATOR-2: Regional STEMI Systems of Care: Results of the Mission: Lifeline STEMI ACCELERATOR-2 Study
James G Jollis | Duke University, Durham, NC


Wednesday, Nov. 15

Late Breaking Clinical Trials 7: Innovative Therapies and Novel Applications
Sanjiv Shah

REDUCE LAP-HF: Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results From the REDUCE LAP-HF I Randomized Controlled Trial
Sanjiv J Shah | Northwestern University, Chicago, IL


Nathan Waldron

TNT-POAF: Temporary Neurotoxin Treatment to Prevent Postoperative Atrial Fibrillation
Nathan H Waldron | Duke University Medical Center, Durham, NC


Mary McDermott

PROPEL: Granulocyte Macrophage Colony-Stimulating Factor With and Without Supervised Exercise to Improve Walking Performance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial
Mary M McDermott | Northwestern University, Chicago, IL


Timothy Henry

ALLSTAR: 6-Month Results of ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: A Randomized, Placebo-Controlled, Double-Blind Study
Timothy D Henry | Cedars-Sinai Heart Institute, Los Angeles, CA


Ronald Victor

HOPE-Duchenne: Cardiosphere-Derived Cells for the Treatment of Duchenne Cardiomyopathy: Results of the Halt cardiOmyopathy ProgrEssion [HOPE]-Duchenne Trial
Ronald Victor | Cedars-Sinai Medical Center, Los Angeles, CA